Welcome to Jiangxi Yuneng Pharmaceutical Co., Ltd.
    Your Position:Home > News Center  > Entreprise's news
    Innovation in the API industry requires both corporate and government
    Source:Chinese websites PublishDate:2019-03-11

    Technological innovation in the API industry is a very complex system engineering innovation system involving pharmacy, chemistry, biology, informatics, engineering, mechanical technology and so on. Foreign original drug research and development often takes more than ten years. Among them, different R&D stages are coordinated by different types and levels of R&D institutions. The success of technological innovation is due to the mature and perfect innovative market system and linkage platform.
    With the increasingly fierce competition in the pharmaceutical market, the market demand for independent innovation of pharmaceutical companies is also increasing day by day, and the pressure for research and development of pharmaceutical innovation is also growing. The API industry is also facing an innovation problem as an important part of the pharmaceutical field.

    At present, R&D outsourcing has become a model for drug innovation development in the pharmaceutical industry in recent years. Due to the imperfect domestic innovation market system and the lack of awareness of the main market for innovation, the result is that research and development outsourcing between domestic pharmaceutical companies and research and development outsourcing cooperation between production, learning and research is lower than that between domestic and foreign pharmaceutical companies. R & D outsourcing cooperation level.
    Because foreign-invested pharmaceutical companies have already moved their R&D institutions into China, they are seeking domestic R&D cooperation and sharing domestic R&D market resources.
    As the main body of innovation in the pharmaceutical industry, pharmaceutical companies should take the initiative to strengthen joint cooperation and actively innovate the market industrial chain; actively strengthen complementary cooperation in different aspects of major scientific and technological projects, and share compensation through technical innovation resources to reduce waste of research and development investment. Accelerating the key technological innovations in the API industry and participating in international R&D outsourcing and winning the process of global competition will be of great benefit.
    Of course, in the process of technological innovation in the API industry, to improve the domestic pharmaceutical innovation market system, it is also necessary to provide a reasonable guidance of national policies. The state should provide more favorable policies and market environment to support independent innovation of pharmaceutical companies.